AI generated image of closeup of skin layers.
Source: Adobe Stock
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

Orthocell (ASX:OCC), has risen more than 7% today after clearing the latest hurdle to distributing its nerve repair product in the U.S. The stock’s bull run over the last two months has seen its share price more than double as investors eye the lucrative $1.6 billion nerve repair market in the States.

There were times during the day it touched as much as +12%, though the Healthcare stock has given some of its green rise back through afternoon trade.

The Perth-based regenerative medicine company completed a critical U.S. FDA 510(k) regulatory study for its nerve repair product, Remplir. The study confirmed Remplir as possessing strong efficacy and safe for use in the surgical repair of peripheral nerves, meeting all FDA requirements.

This milestone clears the decks for a marketing application later this month, with FDA approval expected in the first quarter of 2025.

A 510(k) study aims to validate a device is significantly comparable in safety and efficacy to similar FDA-approved devices. These studies produce critical data required for an application and form a prerequisite to any product marketed in the U.S.

Remplir, in use in Australia, New Zealand, and Singapore, is designed to facilitate high-quality nerve regeneration. It’s a collagen nerve wrap that provides compression-free protection, generating an ideal microenvironment to aid healing. Clinical data demonstrated 85% of nerve reconstructions using Remplir resulted in functional recovery of muscles controlled by the repaired nerve.

The company engaged with three globally respected researchers, including Professors Bill Walsh of UNSW and Minghao Zheng of the University of Western Australia. The study focussed on evaluating nerve regeneration in 72 rats using Remplir, a comparator product, and a control group.

Eventual results showed Remplir’s efficacy in restoring motor and sensory functions and an absence of inflammation or scarring.

Orthocell CEO Paul Anderson said: “These results validate the superior outcomes of Remplir and provide critical data for FDA clearance. We are excited about bringing this transformative product to the world’s largest healthcare market.”

Orthocell has been 87 cents per share just before close Sydney time.

Join the discussion: See what HotCopper users are saying about Orthocell Limited and be part of the conversations that move the markets.

The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.

occ by the numbers
More From The Market Online

Market Close: ASX slides 1.58% as global AI sell-off rattles investors

My nerves, along with my portfolio, have taken a beating over the last couple of weeks – and I’m sick of seeing red!

Market Close: Materials drag ASX lower as seven sectors finish higher

The Australian share market finished lower on Monday, with weakness across the resources sector weighing on the broader market despite gains across most

Market Close: ASX slides as resources and miners lead broad market sell-off

The Australian sharemarket came under renewed pressure on Tuesday 17th Nov, with selling extending across almost every sector as resources and energy

Market Close: ASX slides as technology and materials stocks lead broad market decline

The Australian share market finished lower on Wednesday, with the S&P/ASX 200 falling 0.69% to close at 8,821.80 points.